Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Sign Up to like & getrecommendations! Published in 2018 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2018.01.011
Abstract: Leiomyosarcomas (LMS) are rare tumors with poor prognosis owing to the high rate of recurrent and metastatic disease. The combination of doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM) results in moderate response rates of 10%-30%.… read more here.
Keywords: doxorubicin treatment; treatment; treatment advanced; aim regimen ... See more keywords